Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2010

01-12-2010 | Case Report

Primary aldosteronism due to adrenocortical adenoma with concurrent ileum carcinoid tumor: case report

Authors: L. Zinnamosca, L. Petramala, D. Cotesta, C. Marinelli, S. Sciomer, G. Cavallaro, A. Ciardi, R. Massa, G. De Toma, S. Filetti, C. Letizia

Published in: Endocrine | Issue 3/2010

Login to get access

Abstract

Primary aldosteronism (PA) with synchronous carcinoid syndrome is extremely rare occurrence. In this article, we describe a case of PA due to adrenocortical adenoma (“aldosteronoma”) and concurrent malignant carcinoid tumor of ileum. The patient was treated with synchronous right adrenalectomy and resection of the ileum. This case is an example of concomitant presence of two types of tumors, effectively managed surgically. We report a case of a nonclassical form of multiple endocrine neoplasia type 1 (MEN 1) syndrome.
Literature
1.
G.P. Rossi, G. Bernini, C. Caliumi, G. Desideri, B. Fabris, C. Ferri, C. Ganzaroli, G. Giacchetti, C. Letizia, M. Maccario, F. Mallamaci, M. Mannelli, M.J. Mattarello, A. Moretti, G. Palumbo, G. Parenti, E. Porteri, A. Semplicini, D. Rizzoni, E. Rossi, M. Boscaro, A.C. Pessina, F. Mantero, PAPY Study Investigators, A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol. 48, 2293–2300 (2006)CrossRefPubMed
2.
L. Mosso, C. Carvajal, A. González, A. Barraza, F. Avila, J. Montero, A. Huete, A. Gederlini, C.E. Fardella, Primary aldosteronism and hypertensive disease. Hypertension 42, 161–165 (2003)CrossRefPubMed
3.
R.D. Gordon, M. Stowasser, T.J. Tunny, S.A. Klemm, J.C. Rutherford, High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin. Exp. Pharmacol. Physiol. 21, 315–318 (1994)CrossRefPubMed
4.
K.C. Loh, E.S. Koay, M.C. Khaw, S.C. Emmanuel, W.F. Young Jr, Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J. Clin. Endocrinol. Metab. 85, 2854–2859 (2000)CrossRefPubMed
5.
G.P. Rossi, A.C. Pessina, A.M. Heagerty, Primary aldosteronism: an update on screening, diagnosis and treatment. J. Hypertens. 26, 613–621 (2008)CrossRefPubMed
6.
H. Abe, K. Kubota, T. Noie, W. Kimura, M. Makuuchi, A rare combination consisting of primary hyperaldosteronism and glucagonoma. Am. J. Gastroenterol. 94, 1397–1401 (1999)CrossRefPubMed
7.
R.F. Berbarie, M. Emmett, N.A. Breslau, Quiz page. Secondary hypertension with contralateral pheochromocytoma and aldosteronoma. Am. J. Kidney Dis. 46(1), A51, e1-3 (2005)
8.
M. Astegiano, F. Bresso, B. Demarchi, N. Sapone, D. Novero, G. Palestro, A. Resegotti, R. Pellicano, M. Rizzetto, Association between Crohn’s disease and Conn’s syndrome. A report of two cases. Panminerva Med. 47, 61–64 (2005)PubMed
9.
M. Honda, T. Tsukada, T. Horiuchi, R. Tanaka, K. Yamaguchi, T. Obara, H. Miyakawa, T. Yamaji, M. Ishibashi, Primary hyperparathyroidism associated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. Intern. Med. 43, 310–314 (2004)CrossRefPubMed
10.
A. Beckers, R. Abs, P.J. Willems, B. van der Auwera, K. Kovacs, M. Reznik, A. Stevenaert, Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus. J. Clin. Endocrinol. Metab. 75, 564–570 (1992)CrossRefPubMed
11.
12.
G. Aggarwal, K. Obideen, M. Wehbi, Carcinoid tumors: what should increase our suspicion? Clevel. Clin. J. Med. 75, 849–855 (2008)CrossRef
13.
J.C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, J.E. Mares, E.K. Abdalla, J.B. Fleming, J.N. Vauthey, A. Rashid, D.B. Evans, One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063–3072 (2008)CrossRefPubMed
14.
I.M. Modlin, K. Oberg, D.C. Chung, R.T. Jensen, W.W. de Herder, R.V. Thakker, M. Caplin, G. Delle Fave, G.A. Kaltsas, E.P. Krenning, S.F. Moss, O. Nilsson, G. Rindi, R. Salazar, P. Ruszniewski, A. Sundin, Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9, 61–72 (2008)CrossRefPubMed
15.
B. Eriksson, G. Klöppel, E. Krenning, H. Ahlman, U. Plöckinger, B. Wiedenmann, R. Arnold, C. Auernhammer, M. Körner, G. Rindi, S. Wildi, Frascati Consensus Conference participants. Consensus guidelines for the management of patients with digestive neuroendocrine tumors—well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87, 8–19 (2008)CrossRefPubMed
16.
J.D. Blumenfeld, J.E. Sealey, Y. Schlussel, E.D. Vaughan Jr., T.A. Sos, S.A. Atlas, F.B. Müller, R. Acevedo, S. Ulick, J.H. Laragh, Diagnosis and treatment of primary hyperaldosteronism. Ann. Intern. Med. 121, 877–885 (1994)PubMed
17.
18.
J.K. Ramage, A.H. Davies, J. Ardill, N. Bax, M. Caplin, A. Grossman, R. Hawkins, A.M. McNicol, N. Reed, R. Sutton, R. Thakker, S. Aylwin, D. Breen, K. Britton, K. Buchanan, P. Corrie, A. Gillams, V. Lewington, D. McCance, K. Meeran, A. Watkinson, UKNETwork for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 54 Suppl 4, iv1-16 (2005)
19.
W.W. de Herder, Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome). Best Pract. Res. Clin. Gastroenterol. 19, 705–715 (2005)CrossRefPubMed
20.
21.
M.A. Maggard, J.B. O’Connell, C.Y. Ko, Updated population-based review of carcinoid tumors. Ann. Surg. 240, 117–122 (2004)CrossRefPubMed
22.
I.M. Modlin, M. Kidd, I. Latich, M.N. Zikusoka, M.D. Shapiro, Current status of gastrointestinal carcinoids. Gastroenterology 128, 1717–1751 (2005)CrossRefPubMed
23.
A.N. van der Horst-Schrivers, A.N. Wymenga, T.P. Links, P.H. Willemse, I.P. Kema, E.G. de Vries, Complications of midgut carcinoid tumors and carcinoid syndrome. Neuroendocrinology 80, 28–32 (2004)CrossRefPubMed
24.
25.
F. Assadi, Diagnosis of hypokalemia: a problem-solving approach to clinical cases. Iran. J. Kidney Dis. 2, 115–122 (2008)PubMed
26.
G.W. Herd, A case of primary hyperparathyroidism, primary hyperaldosteronism and Cushing’s disease. Acta Endocrinol. (Copenh) 107, 371–374 (1984)
27.
A. Fertig, M. Webley, J.A. Lynn, Primary hyperparathyroidism in a patient with Conn’s syndrome. Postgrad. Med. J. 56, 45–47 (1980)CrossRefPubMed
28.
D.E. Hellman, M. Kartchner, N. Komar, D. Mayes, M. Pitt, Hyperaldosteronism, hyperparathyroidism, medullary sponge kidneys, and hypertension. JAMA 244, 1351–1353 (1980)CrossRefPubMed
29.
R.F. Gagel, S.J. Marx, Multiple endocrine neoplasia, in Williams Textbook of Endocrinology 11th edn, ed. by P.R. Larsen, M. Kroenenberg, S. Helmed, K. Polonsky (WB Saunders & Company, Orlando, 2007) (Section X, Chap 40)
30.
A. Falchetti, F. Marini, E. Luzi, F. Tonelli, M.L. Brandi, Multiple endocrine neoplasms. Best Pract. Res. Clin. Rheumatol. 22, 149–163 (2008)CrossRefPubMed
31.
S.C. Chandrasekharappa, S.C. Guru, P. Manickam, S.E. Olufemi, F.S. Collins, M.R. Emmert-Buck, L.V. Debelenko, Z. Zhuang, I.A. Lubensky, L.A. Liotta, J.S. Crabtree, Y. Wang, B.A. Roe, J. Weisemann, M.S. Boguski, S.K. Agarwal, M.B. Kester, Y.S. Kim, C. Heppner, Q. Dong, A.M. Spiegel, A.L. Burns, S.J. Marx, Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276, 404–407 (1997)CrossRefPubMed
32.
S.S. Guo, M.P. Sawicki, Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1. Mol. Endocrinol. 15, 1653–1664 (2001)CrossRefPubMed
Metadata
Title
Primary aldosteronism due to adrenocortical adenoma with concurrent ileum carcinoid tumor: case report
Authors
L. Zinnamosca
L. Petramala
D. Cotesta
C. Marinelli
S. Sciomer
G. Cavallaro
A. Ciardi
R. Massa
G. De Toma
S. Filetti
C. Letizia
Publication date
01-12-2010
Publisher
Springer US
Published in
Endocrine / Issue 3/2010
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-010-9394-5

Other articles of this Issue 3/2010

Endocrine 3/2010 Go to the issue

Original Article

Effects of sex steroid hormones, thyroid hormone levels, and insulin regulation on thyrotoxic periodic paralysis in Chinese men

Original Article

Clinical, biochemical, and molecular findings in Argentinean patients with goitrous congenital hypothyroidism

Original Article

Metabolic acidosis as a complication of intravenous dextrose administration in a patient with insulinoma

Original Article

Analysis of differential gene expression by fiber-optic BeadArray and pathway in prolactinomas

Case Report and Review

Exogenous Cushing’s syndrome due to topical corticosteroid application: case report and review literature

Invited Review

Extrapituitary growth hormone
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits